American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients

Transplant Cell Ther. 2023 Apr;29(4):222-227. doi: 10.1016/j.jtct.2023.01.011. Epub 2023 Jan 14.

Abstract

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and then answered FAQs and finalized topics with harmonized recommendations made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This sixth guideline in the series focuses on invasive candidiasis (IC) with FAQs to address epidemiology, clinical diagnosis, prophylaxis, and treatment of IC, plus special considerations for pediatric, cord blood, haploidentical, and T cell-depleted HCT recipients and chimeric antigen receptor T cell recipients, as well as future research directions.

Keywords: Candida; Diagnosis; Epidemiology; Guidelines; Hematopoietic cell transplantation; Invasive candidiasis; Prophylaxis; Treatment.

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Candidiasis, Invasive* / epidemiology
  • Candidiasis, Invasive* / therapy
  • Child
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Transplant Recipients
  • United States / epidemiology

Supplementary concepts

  • Systemic candidiasis